慢性心房纤颤患者口服华法林预防脑栓塞临床观察.docVIP

慢性心房纤颤患者口服华法林预防脑栓塞临床观察摘要：目的：探索华法林对于慢性心房纤颤患者抗凝治疗的安全性及疗效。方法：对符合本研究标准的50例慢性心房纤颤患者随机分为治疗组和对照组。治疗组28例，给予华法林1.5-2.5mg/天开始，监测国际标准化比值（INR），连续观察4周，目标INR2-3（年龄大于75岁的患者INR1.6-2.5），后每月复查INR，根据INR结果调整华法林口服剂量。对照组22例，给予拜阿司匹林片100mg/天。门诊随访记录出血并发症和脑栓塞并发症。结果：两组出血并发症，差异无统计学意义（P＞0.05），脑栓塞发生率治疗组显著低于对照组（P＜0.05）。结论：慢性心房纤颤的患者适量服用华法林抗凝治疗是安全有效。 关键词:心房纤颤华法林 有效性 安全性 The chronic atrium filament trembles the patient to take orally Hua Falin to prevent the cerebral embolism clinical observation Wang Xianying Abstract:Objective:Explores Hua Falin to tremble the patient regarding the chronic atrium filament to prevent clotting the treatment security and the curative effect.Methods：To conforms to this research standard 50 example chronic atrium filament to tremble the patient to divide into the treatment group and the control group stochastically.The treatment group 28 examples,give Hua Falin the 1.5-2.5mg/day start,monitor international standardization ratio (INR),observes 4 weeks continuously,goal INR2-3 (age is bigger than 75 year-old patient INR1.6-2.5),the latter each month reexamines INR,adjusts Hua Falin according to the INR result to take orally the dosage.The control group 22 examples,give do obeisance the aspirin piece 100mg/day.The outpatient service makes a follow-up visit the record hemorrhage complication and the cerebral embolism complication.Results：Two group of hemorrhage complications,the difference non-statistics significance (P0.05),the cerebral embolism formation rate treatment group obviously is lower than the control group (P0.05).Conclusion：The chronic atrium filament trembles the patient right amount takes Hua Falin to prevent clotting the treatment is safe effective. Keywords：The atrium filament trembles Hua Falin the Validity Security 【中图分类号】R544【文献标识码】B 【文章编号】1008-1879(2010)11-0068-01 房颤是一种十分常见的心律失常，在我国30岁以上的人群中房颤的患病率为0.77%，并随年龄而增加。房颤是心源性脑栓塞的最常见原因，而且是脑卒中的独立危险因素。故预防房颤脑栓塞十分重要，为此我们临床观察了华法林与阿司匹林的不同抗栓效果，总结如下。 1 资料与方法 1.1 病历资料：入院标准：①房颤发作1年以上；②有一个以上的高危因